BioNexus Gene Lab Corp
No enriched coverage for $BGLC in the last 7 days.
No SEC Form 4 filings for $BGLC in the last 30 days.
This article provides detailed financial information and performance data for BioNexus Gene Lab Corp (BGLC) traded on NASDAQ. It includes stock price charts, key financial stats, company overview, news, and technical analysis, highlighting its current market capitalization and recent stock movements. The company operates in distribution services and also develops liquid biopsy tests.
BioNexus Gene Lab Corp. (NASDAQ:BGLC) held its 2025 annual meeting on December 24, where shareholders approved four key proposals. These included the election of four director nominees, the adoption of the company’s 2025 Equity Incentive Plan, and the ratification of JP Centurion & Partners PLT as their independent public accounting firm. An adjournment proposal for soliciting additional proxies was also approved.
BioNexus Gene Lab Corp. announced definitive agreements with Fidelion Diagnostics and Tongshu Biotechnology to commercialize VitaGuard, a liquid biopsy platform for minimal residual disease (MRD) testing. The partnership grants BioNexus commercialization rights in ASEAN, focusing on Singapore and Malaysia, and involves share exchanges between the companies. This collaboration aims to enhance accessibility of MRD testing in Southeast Asia and explore AI and companion-diagnostic programs.
